AKBA 10-Q: SEC filing
Akebia Therapeutics
Filed with the SEC on · accession 0001517022-26-000084
AKBA filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Akebia Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, reporting financial results including product revenue and license/collaboration revenue, along with details on its term loan facility and Vifor license agreement.
Key details
✦ Ask GOAX AI about this filing — what it means for AKBA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AKBA?
Click hereFrequently asked questions
What did AKBA file with the SEC on Nov 5, 2026?
AKBA filed a 10-Q (SEC filing). Akebia Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, reporting financial results including product revenue and license/collaboration revenue, along with details on its term loan facility and Vifor license agreement.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other AKBA SEC filings
- 8-K · Delisting noticeOct 23, 2026
- 8-K · Executive departureOct 14, 2026
- 8-K · SEC filingAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · Fda approvalJun 30, 2026
- 144 · Insider sale plannedJun 29, 2026
- 8-K · Board changeJun 22, 2026
- 8-K · SEC filingMay 7, 2026
- 10-Q · SEC filingMay 7, 2026
- DEF 14A · Board changeApr 28, 2026
Get alerts when AKBA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days